Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
Antitumor activity of four modified on amino sugar moiety derivatives of daunorubicin was compared with activity of two commercial preparations of the parental drug in tests against P 388 leukemia in mice. Tested analogs appeared to be similarly effective as the reference drugs, but two of them, DR-2 and DR-19, were found to be significantly less potent.
D000818:Animals; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004351:Drug Resistance; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D013329:Structure-Activity Relationship
D003630:Daunorubicin